Literature DB >> 3871195

Decreased protective efficacy of reduced and alkylated human immune serum globulin in experimental infection with Haemophilus influenzae type b.

J R Schreiber, V A Barrus, G R Siber.   

Abstract

Conventionally prepared immune serum globulin frequently produces severe side effects when administered intravenously. A modified preparation in which 4 to 5 interchain disulfide bonds have been reduced and alkylated has been made for intravenous use. However, reduction and alkylation may affect Fc-mediated functions of immunoglobulin G, particularly its ability to fix complement by the classical pathway. To determine whether reduction and alkylation alters the protective activity of immune serum globulin in vivo we compared it with two less harshly prepared globulins (pH 4 treated or ultrafiltered) in an infant rat model of Haemophilus influenzae b infection. Antibody binding to the capsular and noncapsular components of H. influenzae b and in vitro bactericidal activity were similar in the globulin preparations. Infant rats were treated with various doses of globulins adjusted to provide identical concentrations of anticapsular antibodies as measured by the Farr radioactive antigen binding assay. At high doses of anticapsular antibody (greater than 1,500 ng per pup), all preparations protected well. At marginal doses (750 ng per pup), however, rats given reduced and alkylated globulin had a significantly greater incidence of bacteremia (P less than 0.05), meningitis (P less than 0.01), and death (P less than 0.05) and a higher magnitude of bacteremia (P less than 0.02) than rats who received pH4-treated or ultrafiltered globulins. These differences were not due to differences in anticapsular antibody concentrations achieved in the serum. The 50% protective serum concentrations of anticapsular antibody in this model were 200 to 300 ng/ml for reduced and alkylated globulin and 100 to 200 ng/ml for acid-treated globulin. Absorption of the globulins with purified H. influenzae b capsule reduced in vitro bactericidal activity and rat protective activity. However, the magnitude of bacteremia was lower in rats receiving absorbed pH 4-treated globulin than in those receiving absorbed reduced and alkylated globulin (P less than 0.05). We conclude that reduced and alkylated immunoglobulin G provides significantly less protective activity against H. influenzae b infection in this model than globulins not so modified, and we suggest that the altered Fc function of the immunoglobulin G, such as the decreased ability to fix complement by the classical pathway or decreased Fc-mediated opsonization, may be responsible for this impairment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871195      PMCID: PMC261489          DOI: 10.1128/iai.47.1.142-148.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

Review 1.  Prophylaxis and treatment of diseases by means of immunoglobulins.

Authors:  S Barandun; F Skvaril; A Morell
Journal:  Monogr Allergy       Date:  1975

2.  Fixation of the first component of complement by immune complexes: effect of reduction and fragmentation of antibody.

Authors:  E M Press
Journal:  Biochem J       Date:  1975-07       Impact factor: 3.857

Review 3.  Complement deficiency states.

Authors:  V Agnello
Journal:  Medicine (Baltimore)       Date:  1978-01       Impact factor: 1.889

Review 4.  The gamma globulins. IV. Therapeutic uses of gamma globulin.

Authors:  C A Janeway; F S Rosen
Journal:  N Engl J Med       Date:  1966-10-13       Impact factor: 91.245

5.  Bactericidal and opsonic properties of C4-deficient guinea pig serum.

Authors:  R K Root; L Ellman; M M Frank
Journal:  J Immunol       Date:  1972-09       Impact factor: 5.422

6.  Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies.

Authors:  J B Robbins; J C Parke; R Schneerson; J K Whisnant
Journal:  Pediatr Res       Date:  1973-03       Impact factor: 3.756

7.  Rapid diagnosis of Hemophilus influenzae type b infections by latex particle agglutination and counterimmunoelectrophoresis.

Authors:  J I Ward; G R Siber; D W Scheifele; D H Smith
Journal:  J Pediatr       Date:  1978-07       Impact factor: 4.406

8.  Intrinsic tritium labeling of the capsular polysaccharide antigen of Haemophilus influenzae type B.

Authors:  P Anderson
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

9.  Antibody-dependent alternative pathway killing of Haemophilus influenzae type b.

Authors:  N P Steele; R S Munson; D M Granoff; J E Cummins; R P Levine
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

10.  Production of Haemophilus influenzae b meningitis in infant rats by intraperitoneal inoculation.

Authors:  A L Smith; D H Smith; D R Averill; J Marino; E R Moxon
Journal:  Infect Immun       Date:  1973-08       Impact factor: 3.441

View more
  8 in total

1.  Antibody to the outer membrane proteins is the dominant opsonic antibody in normal human serum against H. influenzae type b.

Authors:  S V Hetherington
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

2.  Haemophilus influenzae type b opsonins of intravenous immunoglobulins.

Authors:  S Bender; S Hetherington
Journal:  J Clin Immunol       Date:  1987-11       Impact factor: 8.317

3.  Effect of complement depletion on anticapsular-antibody-mediated immunity to experimental infection with Haemophilus influenzae type b.

Authors:  J R Schreiber; C J Basker; G R Siber
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

4.  Relative functional activity of purified human immunoglobulin G against a type III group B streptococcal strain.

Authors:  K S Kim; J H Kang; N F Concepcion; B F Anthony
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

5.  Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits.

Authors:  M Iwata; T Shimozato; H Tokiwa; E Tsubura
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

6.  Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP).

Authors:  Y Machino; H Ohta; E Suzuki; S Higurashi; T Tezuka; H Nagashima; J Kohroki; Y Masuho
Journal:  Clin Exp Immunol       Date:  2010-10-05       Impact factor: 4.330

7.  Lipoprotein e(P4) is essential for hemin uptake by Haemophilus influenzae.

Authors:  J Reidl; J J Mekalanos
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

8.  Antibody blocks acquisition of bacterial colonization through agglutination.

Authors:  A M Roche; A L Richard; J T Rahkola; E N Janoff; J N Weiser
Journal:  Mucosal Immunol       Date:  2014-06-25       Impact factor: 7.313

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.